| Literature DB >> 36187911 |
Sina Nasrollahian1, Mehrdad Halaji2, Akramasadat Hosseini3, Mohammad Teimourian4, Mojtaba Taghizadeh Armaki2, Mehdi Rajabnia2, Hemmat Gholinia5, Abazar Pournajaf2.
Abstract
Background: Infections due to carbapenem-resistant Enterobacteriaceae (CRE) are associated in patients with urinary catheters alarming rate of emergency status. The aim of this study is to investigate the molecular causes of carbapenem resistance among UPEC as well as antimicrobial resistance trends. Additionally, the potential of isolates to produce biofilms, in addition to their clonal and genetic diversity, was investigated. Material and Methods. A cross-sectional study was accomplished on a collection of 76 non-duplicate UPEC isolates obtained from CAUTIs from May 2021 to September 2021. The modified carbapenem inactivation method (mCIM) and EDTA-modified carbapenem inactivation method (eCIM) test was performed for the detection of carbapenemase and metallo-beta-lactamase activity. Also, the presence of carbapenemase genes was determined using PCR assays. In 96-well microtiter plates, biofilm development was evaluated. ERIC-PCR was used to investigate the clonal and genetic variety of isolates.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36187911 PMCID: PMC9507725 DOI: 10.1155/2022/9520362
Source DB: PubMed Journal: Int J Clin Pract ISSN: 1368-5031 Impact factor: 3.149
Figure 1Heatmap and hierarchical clustering of UPEC isolates according to their antibiotic resistance profile of variables showing differences between isolates.
Figure 2The results of mCIM and eCIM; (a) mCIM, (b) eCIM.
Carbapenemase production and its association with antibiotic resistance in UPEC.
| Category | Antibiotics | Carbapenem-positive 48 no. (%) | Carbapenem-negative 10 no. (%) | Unknown-carbapenem 18 no. (%) |
| |||
|---|---|---|---|---|---|---|---|---|
| Resistant | Susceptible | Resistant | Susceptible | Resistant | Susceptible | |||
| Carbapenem | IPM | 14 (29) | 34 (71) | 2 (20) | 8 (80) | 6 (33) | 12 (67) | 0.756 |
| Cephalosporin | CTX | 34 (71) | 14 (29) | 2 (20) | 8 (80) | 15 (84) | 3 (16) | 0.002 |
| CRO | 32 (66) | 16 (44) | 2 (20) | 8 (80) | 16 (89) | 2 (11) | 0.001 | |
|
| ||||||||
| Aminoglycosides | AN | 9 (19) | 39 (81) | 0 | 10 (100) | 3 (16) | 15 (84) | 0.394 |
| GM | 15 (31) | 33 (69) | 0 | 10 (100) | 7 (38) | 11 (62) | 0.080 | |
|
| ||||||||
| Sulfonamides | SXT | 39 (81) | 9 (19) | 6 (60) | 4 (40) | 16 (89) | 2 (11) | 0.177 |
| Quinolones | CP | 32 (66) | 16 (44) | 2 (20) | 8 (80) | 14 (77) | 4 (23) | 0.007 |
| NA | 41 (85) | 7 (15) | 6 (60) | 4 (40) | 15 (84) | 3 (16) | 0.165 | |
|
| ||||||||
| Nitrofurans | FM | 9 (19) | 39 (81) | 2 (20) | 8 (80) | 3 (16) | 15 (84) | 0.972 |
| Genes | Genes | Positive | Negative | Positive | Negative | Positive | Negative | |
|
| 8 (16) | 40 (84) | 1 (10) | 9 (90) | 2 (11) | 16 (89) | 0.774 | |
|
| 0 | 48 (100) | 0 | 10 (100) | 0 | 18 (100) | 0 | |
|
| 2 (4) | 46 (96) | 0 | 10 (100) | 0 | 18 (100) | 0.549 | |
|
| 1 (2) | 47 (98) | 0 | 10 (100) | 1 (5.5) | 17 (94.5) | 0.629 | |
|
| 1 (2) | 47 (98) | 0 | 10 (100) | 0 | 18 (100) | 0.744 | |
|
| 1 (2) | 47 (98) | 0 | 10 (100) | 0 | 18 (100) | 0744 | |
AN: Amikacin; IPM: Imipenem; FM: Nitrofurantoin; SXT: Trimethoprim-Sulfamethoxazole; CTX: Cefotaxime; GM: Gentamicin; CRO: Ceftriaxone; CP: Ciprofloxacin; and NA: Nalidixic acid.
Distribution of metallo-beta-lactamase genes among UPEC isolates.
| Genes | Metallo-beta-lactamase-positive 10 | Metallo-beta-lactamase-negative 66 |
| ||
|---|---|---|---|---|---|
| Positive no. (%) | Negative no. (%) | Positive no. (%) | Negative no. (%) | ||
|
| 1 (10) | 9 (90) | 10 (15) | 56 (85) | 0.666 |
|
| 10 (100) | 0 | 66 (100) | 0 | — |
|
| 0 | 10 (100) | 2 (3) | 64 (96) | 0.577 |
|
| 0 | 10 (100) | 2 (3) | 64 (96) | 0.577 |
|
| 0 | 10 (100) | 1 (1.5) | 65 (98.5) | 0.695 |
|
| 0 | 10 (100) | 1 (1.5) | 65 (98.5) | 0.695 |
Biofilm formation and its association with antibiotic resistance in UPEC.
| Category | Antibiotics | Biofilm-negative 34 | Biofilm-weak and intermediate 42 |
| ||
|---|---|---|---|---|---|---|
| Resistant no. (%) | Susceptible no. (%) | Resistant no. (%) | Susceptible no. (%) | |||
| Cephalosporin | CTX | 24 (70) | 10 (30) | 27 (64) | 15 (36) | 0.561 |
| CRO | 24 (70) | 10 (30) | 26 (62) | 16 (38) | 0.428 | |
| Carbapenem | IPM | 9 (26) | 25 (74) | 13 (30) | 29 (70) | 0.668 |
| Sulfonamides | SXT | 31 (91) | 3 (9) | 30 (71) | 12 (29) | 0.031 |
| Quinolones | CP | 23 (67) | 11 (33) | 25 (59) | 17 (41) | 0.465 |
| NA | 30 (89) | 4 (11) | 32 (76) | 10 (24) | 0.178 | |
| Aminoglycosides | GM | 9 (26) | 25 (74) | 13 (30) | 29 (70) | 0.668 |
| AN | 4 (11) | 30 (89) | 8 (19) | 34 (81) | 0.387 | |
| Nitrofurans | FM | 7 (20) | 27 (80) | 7 (17) | 35 (83) | 0.661 |
| Genes | Genes | Positive | Negative | Positive | Negative | |
|
| 5(14) | 29 (86) | 6 (15) | 36 (85) | 0.959 | |
|
| 0 | 34 (100) | 0 | 42 (100) | — | |
|
| 2 (5) | 32 (95) | 0 | 42 (100) | 0.111 | |
|
| 1 (3) | 33 (97) | 1 (2) | 41 (98) | 0.879 | |
|
| 1 (3) | 33 (97) | 0 | 42 (100) | 0.263 | |
|
| 0 | 34 (100) | 1 (2) | 41 (98) | 0.365 | |
AN: Amikacin; IPM: Imipenem; FM: Nitrofurantoin; SXT: Trimethoprim-Sulfamethoxazole; CTX: Cefotaxime; GM: Gentamicin; CRO: Ceftriaxone; CP: Ciprofloxacin; and NA: Nalidixic acid.
Figure 3Enterobacterial repetitive intergenic consensus polymerase chain reaction (ERIC-PCR) profiles dendrogram of inpatients' uropathogenic Escherichia coli (UPEC) isolates.
Characteristics of the carbapenemase-producing UPEC isolates.
| Strain | Antibiotic resistance pattern | MBL-producing | Biofilm formation | Carbapenemase genes | ERIC type |
|---|---|---|---|---|---|
| 2 | FM, SXT, CTX, CRO, CP, NA | No | Weak | D | |
| 3 | SXT, NA | Yes | Negative | ||
| 5 | AN, IPM, SXT, CTX, CRO, CP, NA | Yes | Negative |
| D |
| 7 | SXT, CTX, CRO, NA | No | Negative | D | |
| 8 | No | Weak | D | ||
| 9 | SXT, CTX, NA | No | Weak | D | |
| 10 | IPM, SXT, CTX, CP | No | Weak | ||
| 11 | FM, CTX, CP, NA | No | Weak | D | |
| 13 | SXT, CP, NA | No | Weak | D | |
| 19 | NA | No | Weak | E | |
| 23 | SXT, CTX, CRO, CP, NA | No | Weak | E | |
| 24 | SXT, CTX, CRO, CP, NA | No | Negative | A | |
| 25 | SXT, CTX, GM, CRO, CP, NA | No | Negative |
| A |
| 28 | CTX, CRO, CP, NA | No | Intermediate | A | |
| 29 | SXT, CTX, CRO, CP, NA | No | Negative | A | |
| 31 | AN, IPM, SXT, CTX, GM, CRO, CP, NA | No | Weak |
| A |
| 34 | CTX, GM, CRO, CP, NA | No | Weak | A | |
| 37 | AN, IPM, SXT, CTX, GM, CRO, CP, NA | No | Intermediate |
| A |
| 38 | IPM, SXT, CTX, CRO, CP, NA | No | Intermediate | A | |
| 40 | IPM, SXT, CTX, CRO, NA | Yes | Weak | A | |
| 41 | IPM, SXT, CTX, CRO, CP, NA | No | Negative | A | |
| 46 | IPM, FM, SXT, CTX, CRO, NA | No | Weak | ||
| 49 | IPM, SXT, NA | No | Negative | C | |
| 50 | SXT, CTX, CRO, NA | No | Weak | B | |
| 51 | AN, SXT, CRO, CP, NA | No | Weak | B | |
| 52 | AN, IPM, FM, SXT, CTX, GM, CRO, CP, NA | No | Negative |
| G |
| 53 | IPM, FM, SXT, CTX, CRO, CP, NA | No | Negative |
| Singleton |
| 54 | No | Negative | C | ||
| 55 | AN, IPM, FM, SXT, CTX, GM, CRO, CP, NA | No | Weak |
| C |
| 56 | SXT, CTX, CRO | Yes | Weak | B | |
| 57 | SXT, NA | No | Negative | ||
| 58 | SXT, CP, NA | Yes | weak Weak | G | |
| 59 | SXT, CP, NA | Yes | Intermediate | G | |
| 60 | CP, NA | No | Negative | C | |
| 61 | SXT | No | Negative | C | |
| 62 | AN, SXT, CTX, GM, CRO, CP, NA | No | Negative | B | |
| 63 | SXT, CTX, CRO, CP, NA | No | Negative | I | |
| 64 | SXT, CTX, GM, CRO, NA | No | Weak | G | |
| 65 | SXT, CTX, CRO, CP, NA | No | Weak | G | |
| 66 | No | Weak | C | ||
| 68 | FM, SXT, CTX, GM, CRO, CP, NA | Yes | Negative | B | |
| 69 | No | Negative | B | ||
| 71 | SXT, CTX, GM, CRO, CP, NA | Yes | Negative | ||
| 72 | AN, IPM, FM, SXT, CTX, GM, CRO, CP, NA | No | Negative |
| H |
| 73 | SXT, CTX, GM, CRO, CP, NA | No | Negative | C | |
| 74 | AN, IPM, FM, SXT, CTX, GM, CRO, CP, NA | No | Weak |
| Singleton |
| 75 | SXT, CTX, GM, CRO, CP, NA | Yes | Negative | H | |
| 76 | SXT, CTX, GM, CRO, CP, NA | No | Negative | H |